Despite the established benefits of angiotensin converting enzyme inhibitors (ACEI) in heart failure, many patients aTe still not receiving these drugs. One reason for this is fear of first dose hypotension (FDH) in patients, particularly elderly ones, taking loop diuretics. It has been suggested that withholding diuretics for 24-48h prior to ACEI introductions may reduce the risk of FDH. Methods To investigate this, we conducted a double-blind cross-over comparison of FDH following an ACEI (Lisinopril 2.5mg) in patients on loop diuretics (40-120mg of fruscmide, or equivalent doses of bumetanide) for heart failure. Twelve elderly patients (over 64 years) were given Lisinopril, on 3 separate occasions, in random order, at least 1 week apart: on usual diuretic, following withdrawal of diuretic for 24h and following 48h withdrawal Results Results were analysed using analysis of variance with repeated measures. There were no significant differences overall (p>0.05) between the 3 periods of diuretic withdrawal, in the lowest blood pressure (BP) recorded, the maximum drop in BP from baseline, the time taken for maximum drop in BP to occur and the overall drop in BP in each of the 3 groups (area over me curve) Conclusions In the population studied, withdrawal of diuretics prior to ACEI introduction did not significantly reduce the risk of FDH. The practice of diuretic withdrawal prior to ACEI cannot be widely recommended NEUROHORMONAL EFFECTS OF AN ANGIOTENSIN 33 CONVERTING ENZYME INHIBITOR IN ELDERLY HEART FAILURE PATIENTS
Introduction
Despite the established benefits of angiotensin converting enzyme inhibitors (ACEI) in heart failure, many patients aTe still not receiving these drugs. One reason for this is fear of first dose hypotension (FDH) in patients, particularly elderly ones, taking loop diuretics. It has been suggested that withholding diuretics for 24-48h prior to ACEI introductions may reduce the risk of FDH. Methods To investigate this, we conducted a double-blind cross-over comparison of FDH following an ACEI (Lisinopril 2.5mg) in patients on loop diuretics (40-120mg of fruscmide, or equivalent doses of bumetanide) for heart failure. Twelve elderly patients (over 64 years) were given Lisinopril, on 3 separate occasions, in random order, at least 1 week apart: on usual diuretic, following withdrawal of diuretic for 24h and following 48h withdrawal Results Results were analysed using analysis of variance with repeated measures. There were no significant differences overall (p>0.05) between the 3 periods of diuretic withdrawal, in the lowest blood pressure (BP) recorded, the maximum drop in BP from baseline, the time taken for maximum drop in BP to occur and the overall drop in BP in each of the 3 groups (area over me curve) Conclusions In the population studied, withdrawal of diuretics prior to ACEI introduction did not significantly reduce the risk of FDH. The practice of diuretic withdrawal prior to ACEI cannot be widely recommended The beneficial effects of Angiotensin Converting Enzyme Inhibitors (ACEI) in heart failure patients are well established. The suppression of angiotensin II production is one beneficial mechanism, but it is postulated that some of the beneficial haemodynamic effects of ACEI result from modulation of other endogenous peptide pathways. Methods: As part of a study to investigate the impact of diuretic withdrawal on haemodynamic changes following an ACEI in 12 elderly heart failure patients, blood samples were taken for plasma renin activity (PRA), atrial natriuretic peptide (ANP), vasoactive intestinal polypeptide (VIP) and metencephalin (MET) prior to administration of Lisinopril 2.5mg and at 4h post dose. Samples were obtained from each patient on 3 trial periods: no diuretic withdrawal, and following diuretic withdrawal for 24h and 48h. Results: Levels of PRA generally rose following ACEI. The change appeared greatest when diuretics were not withdrawn, although the differences did not reach statistical significance (p>0.05). The pattern of change in VIP was less clear, apart from the 24h withdrawal period, when the rise in VIP was significant (p=0.039). There were no significant changes in MET or ANP levels following ACEI. Conclusion: Our data support previous reports of a rise in VIP in response to ACEI. which causes vasodilatation. We were unable to demonstrate a significant rise in MET, which one might expect, as enccphalinase is felt to be similar to angiotensin converting enzyme. Previous reports on the effect of ACEI on ANP are conflicting. The influence of ACEI on other endogenous vasoactive systems and their interactions with ANP are not fully understood, and requires further study Introduction The standard treatment for heart failure includes the use of angiotensin converting enzyme inhibitors (ACEI). When used in doses in clinical trials 1 ' 2 ACEI improve mortality. We examined the initiation, titration and monitoring of ACEI in hospital and community (GP) follow up.
Methodology
Between January and May 1995,64 inpaticnts started on captopril or cnalapril for heart failure, mean age of 75. Retrospective casenote review of blood pressure monitoring(BP), electrolyte monitoring (U&E), and ACEI dose titration Review of GP notes (38 traceable) at 18 months gave data regarding dose ACEI, hospital letter content.
Poster and platform presentations
Results In hospital only 69% of patients started on ACEI had pre and post ACE BP recorded. 92% had one prc ACEI U&E result and only 66% had any post ACEI U&E. ACEI dose had increased in 67% of patients, only 14% reached a therapeutic dose prc-dischargc. At 18 month follow up: 3 further patients achieved therapeutic dose; 24% had any alteration in ACEI dose: 34% of patients still alive had had no hospital follow up; 16% had no further U&E results communicated to GP, 12% of hospital letters advised GP about dose alteration and 17% on U&E monitoring and 16% of patients had GP initiated U&E done, all of whom had attended hospital clinics Overall mortality was 20%
Conclusion
At 18 months only 18% of patients on ACEI reach therapeutic dose as used in trials'" Communication is poor between hospitals and GP's regarding ACEI dose titration and renal monitoring. 
Those patienu who felt least improvement in general health had the greatest vasodepressor response to CSM and the greatest postural hypotension at their pre-pacemaker assessment. The RDR feature has proved an effective treatment for CSS markedly reducing the incidence of syncope, falls, injuries and hospital admissions.
CAUSES AND TREATMENT OF ORTHOSTATIC HYPOTENSION IN OLD ADULTS REFERRED TO A
REGIONAL SYNCOPE SERVICE N Stout, RA Kenny Cardiovascular Investigation Unit, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, United Kingdom. INTRODUCTION Orthostatic hypotension (OH) is defined as a fall in systolic blood pressure of 20mmHg or greater on standing The causes and outcome of OH in the elderly have not been rigorously described METHODS We have defined the cause of OH and the presenting features in 63 consecutive patients diagnosed with OH following referral to a dedicated regional syncope service Cardiovascular assessment included phasic measurement of blood pressure and heart rate during a 2 minute morning stand on at least 2 occasions, carotid sinus massage in both the supine and upright positions and a 70° head-up tilt Autonomic testing was performed on ail OH subjects Normal autonomic function was assumed when at least 3 out 5 tests were
